Charles Schwab’s Mirum Pharmaceuticals MIRM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $19.5M | Buy |
383,160
+55,282
| +17% | +$2.81M | ﹤0.01% | 1688 |
|
|
2025
Q1 | $14.8M | Sell |
327,878
-4,761
| -1% | -$214K | ﹤0.01% | 1780 |
|
|
2024
Q4 | $13.8M | Buy |
332,639
+4,478
| +1% | +$185K | ﹤0.01% | 1879 |
|
|
2024
Q3 | $12.8M | Buy |
328,161
+17,149
| +6% | +$669K | ﹤0.01% | 1914 |
|
|
2024
Q2 | $10.6M | Buy |
311,012
+39,358
| +14% | +$1.35M | ﹤0.01% | 2013 |
|
|
2024
Q1 | $6.82M | Buy |
271,654
+4,973
| +2% | +$125K | ﹤0.01% | 2177 |
|
|
2023
Q4 | $7.87M | Buy |
266,681
+42,110
| +19% | +$1.24M | ﹤0.01% | 2116 |
|
|
2023
Q3 | $7.1M | Buy |
224,571
+152,287
| +211% | +$4.81M | ﹤0.01% | 2093 |
|
|
2023
Q2 | $1.87M | Buy |
72,284
+19,545
| +37% | +$506K | ﹤0.01% | 2569 |
|
|
2023
Q1 | $1.27M | Buy |
52,739
+956
| +2% | +$23K | ﹤0.01% | 2658 |
|
|
2022
Q4 | $1.01M | Buy |
51,783
+1,430
| +3% | +$27.9K | ﹤0.01% | 2766 |
|
|
2022
Q3 | $1.06M | Buy |
50,353
+7,842
| +18% | +$165K | ﹤0.01% | 2779 |
|
|
2022
Q2 | $828K | Buy |
42,511
+27,011
| +174% | +$526K | ﹤0.01% | 2863 |
|
|
2022
Q1 | $342K | Buy |
15,500
+804
| +5% | +$17.7K | ﹤0.01% | 3182 |
|
|
2021
Q4 | $235K | Hold |
14,696
| – | – | ﹤0.01% | 3334 |
|
|
2021
Q3 | $293K | Sell |
14,696
-60,722
| -81% | -$1.21M | ﹤0.01% | 3272 |
|
|
2021
Q2 | $1.3M | Sell |
75,418
-899
| -1% | -$15.5K | ﹤0.01% | 2840 |
|
|
2021
Q1 | $1.51M | Buy |
76,317
+16,764
| +28% | +$332K | ﹤0.01% | 2725 |
|
|
2020
Q4 | $1.04M | Buy |
59,553
+1,066
| +2% | +$18.6K | ﹤0.01% | 2759 |
|
|
2020
Q3 | $1.13M | Buy |
58,487
+43,154
| +281% | +$832K | ﹤0.01% | 2645 |
|
|
2020
Q2 | $299K | Buy |
15,333
+4,255
| +38% | +$83K | ﹤0.01% | 3050 |
|
|
2020
Q1 | $156K | Buy |
+11,078
| New | +$156K | ﹤0.01% | 3056 |
|